Gilead Sciences, Inc. (GILD) Revenue, Earnings & Financial Statements
$167.57NASDAQ: GILDMarket Cap $207.84B
Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Jun 2026 · Source: Financial Modeling Prep (methodology)
Gilead Sciences, Inc. most recently reported annual revenue of $29.4B, net profit of $8.5B. Revenue grew at an average annual rate of 3.6% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Gilead Sciences, Inc.: Revenue fell from $30.4B in 2016 to $29.4B in 2025, a change of -3.1% over 9 years; net profit was positive in all 10 reported years; operating margin moved from 58.0% to 39.7%, a shift of -18.3 percentage points; the most recent year shows net profit of $8.5B.
Income Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Revenue
$30.4B
$26.1B
$22.1B
$22.4B
$24.7B
$27.3B
$27.3B
$27.1B
$28.8B
$29.4B
Operating Expenses
$12.8B
$12.0B
$13.9B
$18.2B
$20.6B
$17.4B
$20.0B
$19.5B
$27.1B
$17.7B
Operating Profit
$17.6B
$14.1B
$8.2B
$4.3B
$4.1B
$9.9B
$7.3B
$7.6B
$1.7B
$11.7B
Operating Margin
58.0%
54.1%
37.1%
19.1%
16.5%
36.3%
26.9%
28.1%
5.8%
39.7%
Other Income
−$536.0M
−$595.0M
−$401.0M
$873.0M
−$2.4B
−$1.6B
−$1.5B
−$746.0M
−$972.0M
−$1.9B
Interest
$964.0M
$1.1B
$1.1B
$995.0M
$984.0M
$1.0B
$935.0M
$944.0M
$977.0M
$1.0B
Depreciation
$1.2B
$1.3B
$1.4B
$1.4B
$1.5B
$2.0B
$2.1B
$2.7B
$2.8B
$2.8B
Profit Before Tax
$17.1B
$13.5B
$7.8B
$5.2B
$1.7B
$8.3B
$5.8B
$6.9B
$690.0M
$9.8B
Tax rate (%)
21.1%
65.7%
30.0%
-4.0%
94.7%
25.1%
21.5%
18.2%
30.6%
13.1%
Net Profit
$13.5B
$4.6B
$5.5B
$5.4B
$123.0M
$6.2B
$4.6B
$5.7B
$480.0M
$8.5B
EPS
$9.94
$3.51
$4.17
$4.22
$0.10
$4.93
$3.64
$4.50
$0.38
$6.78
Quarterly Results — Last 12 Quarters (USD millions)
8 duplicate period labels in the source data were collapsed.
Metric
Sep '23
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$7.0B
$7.1B
$6.7B
$7.0B
$7.5B
$7.6B
$6.7B
$7.1B
$7.8B
$7.9B
$7.0B
$7.8B
Operating Expenses
$4.4B
$5.5B
$11.0B
$4.3B
$6.7B
$5.1B
$4.4B
$4.6B
$4.4B
$4.9B
$4.4B
$18.2B
Operating Profit
$2.6B
$1.6B
−$4.3B
$2.6B
$888.0M
$2.5B
$2.2B
$2.5B
$3.3B
$3.0B
$2.6B
−$10.4B
Operating Margin
37.2%
22.7%
-64.6%
38.0%
11.8%
32.4%
33.5%
34.9%
42.8%
37.7%
37.2%
-133.2%
Interest
$232.0M
$252.0M
$254.0M
$237.0M
$238.0M
$249.0M
$260.0M
$254.0M
$256.0M
$255.0M
$240.0M
$247.0M
Profit Before Tax
$2.3B
$1.7B
−$4.5B
$2.1B
$956.0M
$2.2B
$1.6B
$2.4B
$3.6B
$2.1B
$2.6B
−$10.3B
Tax rate (%)
6.3%
14.3%
7.0%
21.3%
-31.1%
17.8%
20.3%
19.3%
16.2%
-5.0%
21.7%
-2.4%
Net Profit
$2.2B
$1.4B
−$4.2B
$1.6B
$1.3B
$1.8B
$1.3B
$2.0B
$3.1B
$2.2B
$2.0B
−$10.5B
EPS
$1.73
$1.14
−$3.34
$1.29
$1.00
$1.42
$1.04
$1.56
$2.43
$1.74
$1.61
−$8.45
Over the 10 years reported for Gilead Sciences, Inc., borrowings decreased from $26.3B in 2016 to $24.9B in 2025, cash stood at $7.6B in the latest year, shareholders' equity was $1.0M, current assets covered current liabilities 1.55 times.
Balance Sheet — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
$57.0B
$70.3B
$63.7B
$61.6B
$68.4B
$68.0B
$63.2B
$62.1B
$59.0B
$59.0B
Current Assets
$19.6B
$31.8B
$35.8B
$30.3B
$16.0B
$14.8B
$14.4B
$16.1B
$19.2B
$18.3B
Cash
$8.2B
$7.6B
$17.9B
$11.6B
$6.0B
$5.3B
$5.4B
$6.1B
$10.0B
$7.6B
Inventory
$1.6B
$801.0M
$814.0M
$922.0M
$1.7B
$1.6B
$1.5B
$1.8B
$1.7B
$1.8B
Receivables
$4.5B
$3.9B
$3.3B
$3.6B
$4.9B
$4.5B
$4.8B
$4.7B
$4.4B
$4.9B
Fixed Assets
$2.9B
$3.3B
$4.0B
$4.5B
$5.0B
$5.1B
$5.5B
$5.3B
$5.4B
$5.6B
Capital Work in Progress
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Investments
$24.2B
$29.1B
$13.6B
$14.2B
$1.9B
$2.5B
$2.2B
$2.3B
$1.6B
$5.0B
Other Assets
$1.2B
$4.2B
$4.1B
$4.1B
$8.1B
$8.3B
$8.3B
$8.3B
$8.3B
$8.3B
Total Liabilities
$37.6B
$49.8B
$42.1B
$39.0B
$50.2B
$46.9B
$42.0B
$39.4B
$39.7B
$36.4B
Current Liabilities
$9.2B
$11.6B
$10.6B
$9.8B
$11.4B
$11.6B
$11.2B
$11.3B
$12.0B
$11.8B
Borrowings
$26.3B
$33.5B
$27.3B
$24.6B
$31.4B
$26.7B
$25.2B
$25.0B
$26.7B
$24.9B
Other Liabilities
$11.3B
$16.2B
$14.8B
$14.4B
$18.8B
$20.2B
$16.7B
$14.4B
$13.0B
$11.5B
Equity
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
$1.0M
Reserves
$18.9B
$20.4B
$21.4B
$22.5B
$18.2B
$21.1B
$21.2B
$22.8B
$19.3B
$22.7B
For Gilead Sciences, Inc., operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $9.5B; free cash flow was positive in 10 of 10 years; financing activities used $2.4B in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 10 Years (USD millions)
Metric
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Operating Cash Flow
$17.0B
$11.9B
$8.4B
$9.1B
$8.2B
$11.4B
$9.1B
$8.0B
$10.8B
$10.0B
Investing Cash Flow
−$12.7B
−$16.7B
$13.4B
−$8.6B
−$15.3B
−$3.7B
−$3.2B
−$2.9B
−$4.0B
−$5.4B
Financing Cash Flow
−$11.7B
−$1.3B
−$3.4B
−$1.9B
−$1.7B
−$691.0M
−$1.6B
−$1.3B
−$1.4B
−$2.4B
Net Cash Flow
−$4.6B
−$641.0M
$10.4B
−$6.3B
−$5.6B
−$659.0M
$74.0M
$673.0M
$3.9B
−$2.4B
Free Cash Flow
$16.3B
$11.3B
$7.5B
$8.3B
$7.5B
$10.8B
$8.3B
$7.4B
$10.3B
$9.5B
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.40
EV / EBITDA
162.33
FCF Yield
6.82%
Quick Ratio
1.09
Interest Coverage
-1.50
Return 1Y
37.57%
Return 3Y
147.25%
Return 5Y
200.55%
Gilead Sciences, Inc. (GILD) financials — frequently asked questions
What is Gilead Sciences, Inc.'s annual revenue?
Gilead Sciences, Inc. (GILD) reported annual revenue of $29.4B in its most recent fiscal year.
What is Gilead Sciences, Inc.'s net profit?
Gilead Sciences, Inc. (GILD) reported net profit of $8.5B in its most recent fiscal year.
What is GILD EV/EBITDA?
Gilead Sciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is 162.33.
Revenue and earnings of other Drug Manufacturers - General stocks